TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: No relapse during treatment or follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EHP-30 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak PAED scores for EA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POV
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores on the ward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade A acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytomegalovirus infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of adverse events leading to early discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of vision impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of hearing testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of new disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary glycosaminoglycan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder range of motion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: retinal/subretinal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Follow-up HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative spherical equivalent refraction of ±0.5 diopters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative total root‐mean‐square of higher order aberrations (HOAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: NIHSS score at 1 and 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Barthel Index at 1 and 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Erectile dysfunction treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton depression scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring postoperative piritramide
Endpoint domain: Adverse events/effects
Primary endpoint: Anesthesia induction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Support for PrEP availability outside a clinical trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concerns about current evidence for PrEP
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of PrEP among healthcare professionals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change in cortical brain amyloid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin capacitance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma levels of N‐BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of MMP‐9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall satisfaction with alosetron treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of choroidal involvement in ocular sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in specific symptoms (SNOT22 scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in endoscopic appearance of nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFM function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nocturnal urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of effort urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial inner diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AT1 mRNA and protein levels in the left atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: liver function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of serum PCIII, CIV, HA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver pathologic grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of ALT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to generate airway pressure of 20 cm water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to ventilate manually
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to arrest uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 physical health scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom from any atrial arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of TIPS dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of permanent colostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rates of local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean central flap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Heart Rate (HR) at rest, AeT, AnT, and maximal workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of maximal heart rate (%HRmax) at rest, AeT, and AnT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relief from postdural puncture headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3 or 4 treatment-emergent drug-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Implementation rates of health education
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ursodeoxycholic acid
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of absorption (T(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of absorption (AUC(0-30 min))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive temporal artery biopsy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rise in Hb at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: rate of continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal cystometric capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-score ≤-2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Prevalent vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Cost per case found
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: transfusion cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 48-h mortality
Endpoint domain: Mortality/survival
Primary endpoint: Swelling visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic disease activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clustering of newly incident lanca users
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clustering of recently active lanca use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of lanca use with social rank
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Shoulder pain and disability (SPADI scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measures (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: surgical specimen size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: resection volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systemic Embolism Events (SEE)
Endpoint domain: Mortality/survival
Primary endpoint: Moderately severe to severe symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuation of contraceptive method
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean relapse time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean owner GAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to long-acting inhalers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rehabilitation exercise frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS-T score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS-P score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS-N score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical intervention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interscan variability of CAC area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interscan variability of CAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual lesion variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: defibrillation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: smoking abstinence rates
Endpoint domain: Mortality/survival
Primary endpoint: Quality-adjusted life year (QALY) gained
Endpoint domain: Mortality/survival
Primary endpoint: Life-year gained (LYG)
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of HIV-1 infection
Endpoint domain: Mortality/survival
Primary endpoint: Visick score 6 months after operation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body weight 6 months after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNI 6 months after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for analgesic medicine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to retainer wear
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: re-donation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to death or first COPD-related hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Endorsement of treatment component occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Incontinence-Associated Dermatitis (IAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to onset of Incontinence-Associated Dermatitis (IAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to solid food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD3 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastrointestinal transit times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cognitive processing speed and accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived susceptibility to diabetes complications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain free walking distance (PFWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reoperation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal diabetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neonatal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of GSK1440115
Endpoint domain: Adverse events/effects
Primary endpoint: Bronchodilation in asthmatics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma levels of ET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma levels of sP-sel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma levels of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvement in libido
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: improvement in somatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: complete healing success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ cell count decline rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect sizes for trauma-focused psychotherapies (TFPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of gastric acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: control of gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lens centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens wear duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative shoulder and abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing of the first analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change in arylesterase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistence with CMF
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUC(0-10h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular isovolumetric relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Septal E' increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of N-terminal pro brain natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of exact agreement of grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of instances of examiners differing by more than one grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in dialysate glycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in plasma FFA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual field improvement (Goldmann perimetry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field improvement (Humphrey perimetry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of personal activities of daily living (GAS score)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: MF at the beginning of isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: root mean square during isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPT over the deltoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postsurgical intensity of the host-mediated inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gut colonization by yeasts or gram‐negative bacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: use of antimicrobials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24h postoperative quality of recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: bladder neck mobility during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross-sectional area of the urethra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-day bladder diary improvements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness in treating hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of proxodolol
Endpoint domain: Adverse events/effects
Primary endpoint: Number of items reproduced in free recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in physical health as assessed by the SIP
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in mobility as assessed by the SIP
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in mental health as assessed by the HSCL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: uptake of colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of ≥G2 subjective xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: recovery of parotid salivary flow at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total attendance at organized screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sensitivity for early diagnosis of hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for early diagnosis of hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intima-media thickness of the common carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cognitive scores on the Bayley Scales of Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-Age Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glaucoma progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to hepatitis B vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean forced expiratory volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean forced midexpiratory flow levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes